BRIEF-Contineum Therapeutics Expands Clinical Development Of PIPE-791

Reuters

18 Nov 2024

Nov 18 (Reuters) - Contineum Therapeutics Inc :

* CONTINEUM THERAPEUTICS EXPANDS CLINICAL DEVELOPMENT OF PIPE-791 WITH FDA AUTHORIZATION OF ITS INVESTIGATIONAL NEW DRUG $(IND.AU)$ APPLICATION FOR CHRONIC PAIN

* CONTINEUM THERAPEUTICS INC: PHASE 1B STUDY FOR POTENTIAL TREATMENT OF OSTEOARTHRITIS AND LOW BACK PAIN EXPECTED TO COMMENCE IN Q1 OF 2025

* CONTINEUM THERAPEUTICS INC - PHASE 1B STUDY FOR PIPE-791 TO BEGIN IN Q1 2025

* CONTINEUM THERAPEUTICS INC - TOPLINE DATA FROM PIPE-791 STUDY EXPECTED IN EARLY 2026

* CONTINEUM THERAPEUTICS INC - EXPECTS $213.9 MILLION CASH TO FUND OPERATIONS THROUGH 2027

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2484162753"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484162753\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2484162753?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484162753","market":"us","top_or_hot":-1,"title":"BRIEF-Contineum Therapeutics Expands Clinical Development Of PIPE-791","media":"Reuters","content":"<html><body><p>Nov 18 (Reuters) - Contineum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * CONTINEUM THERAPEUTICS EXPANDS CLINICAL DEVELOPMENT OF PIPE-791 WITH FDA AUTHORIZATION OF ITS INVESTIGATIONAL NEW DRUG <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> APPLICATION FOR CHRONIC PAIN</p><p>   * CONTINEUM THERAPEUTICS INC: PHASE 1B STUDY FOR POTENTIAL TREATMENT OF OSTEOARTHRITIS AND LOW BACK PAIN EXPECTED TO COMMENCE IN Q1 OF 2025</p><p>   * CONTINEUM THERAPEUTICS INC - PHASE 1B STUDY FOR PIPE-791 TO BEGIN IN Q1 2025</p><p>   * CONTINEUM THERAPEUTICS INC - TOPLINE DATA FROM PIPE-791 STUDY EXPECTED IN EARLY 2026</p><p>   * CONTINEUM THERAPEUTICS INC - EXPECTS $213.9 MILLION CASH TO FUND OPERATIONS THROUGH 2027</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Contineum Therapeutics Expands Clinical Development Of PIPE-791</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Contineum Therapeutics Expands Clinical Development Of PIPE-791\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-18 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Nov 18 (Reuters) - Contineum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * CONTINEUM THERAPEUTICS EXPANDS CLINICAL DEVELOPMENT OF PIPE-791 WITH FDA AUTHORIZATION OF ITS INVESTIGATIONAL NEW DRUG <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> APPLICATION FOR CHRONIC PAIN</p><p>   * CONTINEUM THERAPEUTICS INC: PHASE 1B STUDY FOR POTENTIAL TREATMENT OF OSTEOARTHRITIS AND LOW BACK PAIN EXPECTED TO COMMENCE IN Q1 OF 2025</p><p>   * CONTINEUM THERAPEUTICS INC - PHASE 1B STUDY FOR PIPE-791 TO BEGIN IN Q1 2025</p><p>   * CONTINEUM THERAPEUTICS INC - TOPLINE DATA FROM PIPE-791 STUDY EXPECTED IN EARLY 2026</p><p>   * CONTINEUM THERAPEUTICS INC - EXPECTS $213.9 MILLION CASH TO FUND OPERATIONS THROUGH 2027</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2484162753","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484162753","pubTimestamp":1731936025,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 18  - Contineum Therapeutics Inc   :   * CONTINEUM THERAPEUTICS EXPANDS CLINICAL DEVELOPMENT OF PIPE-791 WITH FDA AUTHORIZATION OF ITS INVESTIGATIONAL NEW DRUG  APPLICATION FOR CHRONIC PAIN   * CONTINEUM THERAPEUTICS INC: PHASE 1B STUDY FOR POTENTIAL TREATMENT OF OSTEOARTHRITIS AND LOW BACK PAIN EXPECTED TO COMMENCE IN Q1 OF 2025   * CONTINEUM THERAPEUTICS INC - PHASE 1B STUDY FOR PIPE-791 TO BEGIN IN Q1 2025   * CONTINEUM THERAPEUTICS INC - TOPLINE DATA FROM PIPE-791 STUDY EXPECTED IN EARLY 2026   * CONTINEUM THERAPEUTICS INC - EXPECTS $213.9 MILLION CASH TO FUND OPERATIONS THROUGH 2027Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","CTNM":"Contineum Therapeutics, INC.","LENZ":"Therapeutics"},"translate_title":"BRIEF-Contineum Therapeutics扩大PIPE-791的临床开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTNM":1,"LENZ":1},"content_text":"Nov 18 (Reuters) - Contineum Therapeutics Inc   :   * CONTINEUM THERAPEUTICS EXPANDS CLINICAL DEVELOPMENT OF PIPE-791 WITH FDA AUTHORIZATION OF ITS INVESTIGATIONAL NEW DRUG $(IND.AU)$ APPLICATION FOR CHRONIC PAIN   * CONTINEUM THERAPEUTICS INC: PHASE 1B STUDY FOR POTENTIAL TREATMENT OF OSTEOARTHRITIS AND LOW BACK PAIN EXPECTED TO COMMENCE IN Q1 OF 2025   * CONTINEUM THERAPEUTICS INC - PHASE 1B STUDY FOR PIPE-791 TO BEGIN IN Q1 2025   * CONTINEUM THERAPEUTICS INC - TOPLINE DATA FROM PIPE-791 STUDY EXPECTED IN EARLY 2026   * CONTINEUM THERAPEUTICS INC - EXPECTS $213.9 MILLION CASH TO FUND OPERATIONS THROUGH 2027Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}